Cancer is a complex genetic disease that develops from the accumulation of genomic alterations in which germline variations predispose individuals to cancer and somatic alterations initiate and trigger the progression of cancer. For the past 2 decades, genomic research has advanced remarkably, evolving from single-gene to whole-genome screening by using genome-wide association study and next-generation sequencing that contributes to big genomic data. International collaborative efforts have contributed to curating these data to identify clinically significant alterations that could be used in clinical settings. Focusing on breast cancer, the present review summarizes the identification of genomic alterations with high-throughput screening as well as the use of genomic information in clinical trials that match cancer patients to therapies, which further leads to cancer precision medicine. Furthermore, cancer screening and monitoring were enhanced greatly by the use of liquid biopsies. With the growing data complexity and size, there is much anticipation in exploiting deep machine learning and artificial intelligence to curate integrative "Àomics" data to refine the current medical practice to be applied in the near future. Cancer precision medicine aims to provide the right dose of the right drug for the right patient at the right time, based on the genetic profiles of cancer and the individual. 1 To realize this vision, rapid advancement of bioinformatics and biotechnology that contribute to the great expansion of the "omics era" makes it possible to magnify screening from a single gene to the whole genome by using genome-wide genotyping for genome-wide association studies (GWAS) or next-generation sequencing (NGS) for cancer genome profiling studies. Equally, this also starts the requirement for a supercomputer/high-performance cluster computing system and use of cloud space to accommodate the analyses and to store the rapidly accumulating big genomic data. Notably, just like finding a needle in a haystack, the greatest challenge of handling big genomic data is to curate and identify clinically significant variants that could be
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This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. The majority of these mutations are inherited in an autosomal dominant manner. Genetic linkage analysis has successfully localized BRCA1 and BRCA2 as highly penetrant cancer susceptibility genes for hereditary breast-ovarian cancers. 8, 9 Individuals who possess mutations in these highly penetrant genes have a significantly higher risk of developing cancer than those in the general population. Nevertheless, mutations in high-penetrance genes explained only a fraction of the heritability of human cancers. 10 Even though the candidate gene approach, which focuses on the DNA damage response pathway and cancer-related genes, the mutations in CHEK2, PALB2, PTEN and ATM 11-14 confer moderate effects on breast cancer, indicating the necessity to uncover more genetic alterations that are associated with this complex cancer. To better understand genetic inheritance, linkage disequilibrium (LD), which is nonrandom association of alleles at nearby loci, was intensely studied. In the year 2001, the International HapMap Project was started to characterize the LD patterns of individuals from 4 major continents that included Caucasians, Africans, Chinese and Japanese. 15 The database that was established from the HapMap project enabled the selection of representative SNP (tagSNP) for LD blocks, which lead to the possibility of carrying out GWAS by evaluating a reduced number of tagSNP that represented the whole genome. To uncover all SNP for the whole genome, the untyped SNP could be inferred by referring typed SNP of GWAS to the whole genome reference sequence from the 1000 genomes reference database by using genotype imputation analysis. 16 Figure 1 Association of FGFR2 contributes up to 16% of all breast cancers indicating a significant disease burden. FGFR2 is overexpressed in 5%-10% of breast tumors. 19 System biology approach suggests a link between FGFR2 germline variants could reduce a cell's ability to respond to estrogen activation. 20 In contrast, TOX3 expression is Among the novel loci identified by breast cancer GWAS, 2 loci, 8q24.21 and 5p15.33, are of particular interest as they showed pleiotropic effects with multiple cancer susceptibility. 24, 25 In locus 8q24.21, 14 independent significant associations were identified from cancer GWAS of breast, prostate, colon, ovarian, bladder, pancreatic cancers and chronic lymphocytic leukemia. 24 All of these variants are clustered within a large gene desert with 2 nearest genes, family with sequence similarity 84 member B (FAM48B) and MYC proto-oncogene (MYC). Several studies hypothesize that the risk regions possess a regulatory element to the well-known F I G U R E 1 Summary workflow of genome-wide association studies (GWAS). GWAS starts from the determination of phenotypes. Genomic DNA extracted from samples was genotyped with chips that contained up to hundreds of thousands of single nucleotide polymorphisms (SNP). Quality control (QC) was carried out on samples and SNP before association studies. Sample quality control includes: (1) sample quality to exclude poorly genotyped samples; (2) identity-by-state analysis to exclude close relatedness samples; and (3) principal component analysis to evaluate population stratification of the sample sets to obtain a homogeneous sample set before carrying out the association study. SNP QC were set to exclude SNP if: (1) they were of low genotype quality; (2) if SNP deviated from normal distribution by evaluating the HardyWeinberg equilibrium in control samples; and (3) if they contained non-polymorphic SNP (minor allele frequency = 0). To evaluate the association distribution, quantile-quantile plots (Q-Q plot) of observed P-value vs expected P-value and genomic inflation factor (k value) were evaluated to eliminate the possibility of population substructure. Manhattan plots of P-value (Àlog 10 ) vs chromosome loci were used to depict an overview of the GWAS, with each dot representing a SNP and each color representing a chromosome. Post-GWAS included: (A) a metaanalysis that combined multiple studies to identify significantly associated SNP; and (B) functional analysis. Two of the most common functional analyses of the identified variants are: (i) electrophoretic mobility shift assay (EMSA) to check the existence of proteins, mainly transcription factors, binding to SNP-contained DNA fragments; and (ii) luciferase reporter assay (comparison of relative luciferase activity) to assess the associated SNP that could affect differential gene expression (as shown in the figure). (C) Other analyses, including gene-based analysis, pathway analysis, polygenic risk estimation, SNP-SNP interaction, SNP-environment interaction etc. could be carried out after GWAS Even though imputation analysis using the GWAS dataset could uncover most of the common variants for the whole genome with high accuracy, it still stands as a challenge to impute relatively rare genotyping before the use of 6-mercaptopurine and camptothecin, respectively, to predict the occurrence of severe adverse events before treatment. 35, 36 Similar to the identification of genetic variants associated with cancer susceptibility, a pharmacogenomics study for breast cancer variants were found to affect Ki-67 response in breast cancer tissues after tamoxifen therapy through a multicenter prospective study. 38 Even though the candidate gene approach in pharmacogenomics studies has successfully identified genes involved in drug response or drug-induced adverse events, it could only explain a small proportion of the mechanism. Genes that are involved in the immunological pathway might play a role in drug-induced adverse events, such as the association of human leukocyte antigen (HLA) alleles with various drug-induced toxicities. 39, 40 GWAS that provides a free-hypothesis approach facilitates the identification of novel genes that are responsible for drug response or druginduced toxicity.
The GWAS of breast cancer pharmacogenomics is mostly divided into 2 categories: drug response that influences breast cancer survival, and breast cancer therapy-induced toxicity. Table 2 summarizes the up-to-date pharmacogenomics studies by using GWAS in breast cancer. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] Most of the studies could not identify variants that surpassed the genome-wide significance threshold, 5.0 9 10 À8 (multiple testing of P = .05 divided by a million independent test SNP), owing to the relatively low statistical power studies that contributed from the small sample size. It is always a challenge for cancer pharmacogenomics studies to recruit an adequate number of samples with uniform therapy for a specific phenotype as the incidence of druginduced adverse events is often low, and cancer therapy often varies in drug combinations, dosing regimens and treatment duration. Nonetheless, more than one-third of patients do not benefit from endocrine therapy owing to intrinsic resistance. 60 Even if therapy is shown to be effective initially, prolonged exposure causes resistance towards the therapy. One of the proposed mechanisms that causes resistance are mutations on the ESR1 gene that render the estrogen receptor from constitutive activation. 61, 62 Hence, monitoring ESR1 mutations could help to assess the resistance of endocrine therapy.
T A B L E 2 Breast cancer pharmacogenomics study
From the perspective of cancer genomics, luminal A subtypes are shown to have the most mutated genes, with the most frequent in PIK3CA, followed by MAP3K1, GATA3, TP53, CDH1 and MAP2K4.
Notably, luminal A tumors harbored inactivating mutations in MAP3K1 and MAP2K4, which represent 2 contiguous steps in the p38-JNK1 stress kinase pathway. 56 Luminal B subtypes showed a diversity of mutated genes that include TP53 and PIK3CA being the most frequent. Significantly, the TP53 pathway remains largely intact in luminal A cancers but is often inactivated in more aggressive luminal B cancers. 56 The high frequency of PIK3CA mutations in this luminal subgroup indicates that inhibitors of this kinase and its related signaling pathway may act as potential druggable targets. 56 Approximately 25% of breast cancer patients are HER2 positive which is associated with decreased overall survival and increased risk of metastasis. 63 HER2 protein (human epidermal growth factor receptor 2) regulates cell growth, proliferation and differentiation.
The establishment of trastuzumab, a humanized monoclonal antibody against HER2-extracellular domain, and lapatinib, an intracellular tyrosine kinase inhibitor that blocks both HER2 and EGFR activation, represent a prominent therapeutic advance for HER-2 breast cancer patients. 64, 65 Findings from a cancer genomics study suggested Gene panel-based targeted sequencing that is used in clinical cancer genomic profiling is designed to sequence genomic "hot spot"
regions that are frequently mutated in human cancer genes or druggable targets by using DNA from the formalin-fixed paraffin- Owing to the invasive method of obtaining biopsy samples from primary or metastatic lesions, there is growing interest in the field of blood-based biomarkers that includes circulating tumor cells (CTC), exosomes and circulating tumor DNA (ctDNA), which, together, is termed liquid biopsy. CTC that are released from the primary tumor and survive in the bloodstream have the potential to seed at secondary sites to form metastases. 84 Importantly, CTC could be used to generate CTC-derived explants (CDX) that show broad similarity with the primary tumor; hence, the response of CDX to therapeutic agents mirrors the patient's response to the same treatment. 85 The major demerit of CTC is that there are only low-input amounts of CTC from the bloodstream that could be isolated using limited capture techniques. 86 Exosomes are small membrane vesicles released from diverse cell types that transfer functional molecules such as DNA, miRNA, proteins and lipid to the recipient cells. 87, 88 Lately, much research has focused on specific exosomal miRNA that reflect pathological changes in cancer and suggests that exosomes are LOW ET AL.
| 503 promising biomarkers. 89, 90 Nevertheless, the isolation and purification of exosomes presently remains a challenge. 86 ctDNA are short DNA fragments that originate from apoptosis and necrosis of normal and tumor cells. 91 ctDNA can be detected in the cell-free fraction of the blood and provide a snapshot of the genetic profiles of primary and metastatic tumor site(s). 92, 93 Mutation status in ctDNA is highly concordant with the corresponding tumor tissue and the level of ctDNA increase corresponds to the stage of cancer. 94 In addition, it is known that ctDNA has superior sensitivity compared to conventional biomarkers, such as CA-153, and has a greater dynamic range that correlates with changes in tumor burden. 95 Because half-time of ctDNA is quite short (about 2 hours), they could reflect the current status of both primary tumors and secondary deposits accurately 
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